Tivic Health Systems, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
VBIO$0.53-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| 2025 | 2024 | |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(8,878) | $(5,655) |
| Less: net loss from discontinued operations | (885) | (1,185) |
| Net loss from continuing operations | (7,993) | (4,470) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock based compensation | 564 | 229 |
| Depreciation | 5 | 3 |
| Amortization of debt discount and debt issuance costs | 97 | — |
| Non-cash interest expense | 48 | |
| Change in fair value of derivative liability | (28) | — |
| Issuance of warrants for services | 93 | — |
| Amortization of right-of-use asset | — | 349 |
| Write-off offering costs related to unclosed financing arrangements | 143 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 78 | 78 |
| Other assets | — | 34 |
| Accounts payable | 139 | (588) |
| Accrued expenses | 235 | (348) |
| Lease liabilities | — | (369) |
| Net cash used in operating activities - continuing operations | (6,619) | (5,082) |
| Net cash used in operating activities - discontinued operations | (380) | (643) |
| Net cash used in operating activities | (6,999) | (5,725) |
| Cash flows from investing activities | ||
| Issuance of note receivable | (124) | — |
| Acquisition of property and equipment | (38) | — |
| Acquisition of licensed technology | (543) | — |
| Net cash used in investing activities | (705) | — |
| Cash flows from financing activities | ||
| Issuance costs in connection with senior convertible note | (172) | — |
| Proceeds from issuance of common stock, net of issuance costs | 2,337 | — |
| Proceeds from issuance of common stock and warrants, net of issuance costs | — | 4,381 |
| Proceeds from issuance of preferred stock and warrants, net of issuance costs | 16,209 | — |
| Proceeds from warrant exercises | 109 | — |
| Offering costs in advance of sale of common stock | (136) | (49) |
| Net cash provided by financing activities | 18,347 | 4,332 |
| Net increase (decrease) in cash and cash equivalents | 10,643 | (1,393) |
| Cash and cash equivalents | ||
| Beginning of period | 2,002 | 3,395 |
| End of period | 12,645 | 2,002 |
| Less: cash and cash equivalents included in discontinued operations | — | — |
| Cash and cash equivalents included in continuing operations | $12,645 | $2,002 |
| Supplemental disclosure on non-cash financing activities | ||
| Convertible note issued in exchange for purchase of Scorpius assets and goodwill | $16,253 | $— |
| Warrants issued to placement agents as non-cash offering fees | $221 | $70 |
| Issuance of common stock and preferred stock in exchange for license | $1,700 | $— |
| Issuance of common stock for equity line of credit commitment fee | $94 | $— |
| Issuance of warrants in exchange for discount on convertible note payable | $9,404 | $— |
| Non-cash recognition of embedded derivative liability on issuance of convertible notes | $320 | $— |
| Dividends declared | $168 | $— |
| Deemed dividends | $10 | $— |
| Write-off of ROU asset and lease liability | $— | $290 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.